Full text is available at the source.
Clinical review of subcutaneous semaglutide for obesity
Summary of under-the-skin semaglutide treatment for obesity
AI simplified
Abstract
Subcutaneous semaglutide at 2.4 mg once weekly resulted in significant weight reduction in a study of 5000 participants with obesity.
- Participants receiving semaglutide experienced a dose-dependent reduction in body weight compared to those on placebo.
- A higher percentage of participants achieved a 5%-10% weight reduction from baseline when treated with semaglutide.
- The study primarily involved middle-aged female participants with Class II obesity.
- Gastrointestinal adverse events were the most common safety concerns associated with semaglutide treatment.
- Further studies, particularly with diverse patient populations and active comparators, are needed to fully assess the efficacy and safety of semaglutide.
AI simplified